Korro Bio's OPERA platform uses engineered oligonucleotides to make precise RNA edits, co-opting endogenous ADAR to correct disease-causing transcripts.
Korro Bio
Korro Bio: Innovating extraordinary treatments for patient care.
Founded
2018Korro Bio: Innovating extraordinary treatments for patient care.
Korro Bio, founded with the mission to transform scientific insights into life-altering treatments, focuses on pioneering RNA editing to revolutionize patient care. The company’s core vision is to rewrite the future of medicine through its innovative RNA editing platform, Oligonucleotide Promo. This technology aims to address the inherent complexities of first-generation editing approaches, offering new therapeutic possibilities for a range of conditions. Korro Bio targets the biotechnology and pharmaceutical markets, striving to deliver groundbreaking treatments that significantly improve patient outcomes.
Notable figures affiliated with Korro Bio include leading scientists and industry experts who contribute to its cutting-edge research and development. The company has garnered attention from prominent investors in the biotech sector, underscoring its potential impact. Key achievements include advancements in RNA editing technologies and the development of promising therapeutic candidates. Korro Bio's work has the potential to make a profound impact on the treatment landscape, offering hope and new possibilities for patients with previously untreatable conditions.
Companies similar to Korro Bio include Amber Bio, Wave Life Sciences, Ochre Bio and Shape Therapeutics.
Korro Bio was founded in 2018.
Korro Bio's headquarters is located in Cambridge, MA, US.
Korro Bio's most recent funding round was for $116M (USD) in January 2022.
As of Jan 5, 2022, Korro Bio has disclosed funding of $207.5M (USD). Undisclosed round amounts are excluded.
Korro Bio has 99 employees as of Feb 5, 2024.
Shape Therapeutics
shapetx.com